Clinical research in Argentina’s oncology sector is driving significant advancements in cancer treatment, according to an industry report reviewed in September 2024. This research connects scientific discovery to medical practice through a network of public hospitals, academic institutions, and high-complexity private centers.
Argentina’s Oncology Trials Bridge Lab Discovery and Bedside Care
Over the past two decades, cancer treatment has shifted toward therapies that modify immune responses, block specific molecular targets, and attack tumors with precision. According to data released in September 2024 by the Agencia Noticias Argentinas, clinical trials serve as the controlled environment necessary to evaluate these new treatments before they reach the market.
Strict Regulatory Oversight and Institutional Protocols
These protocols operate under the supervision of independent medical ethics committees and maintain permanent regulatory control by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).
How Immunotherapy and Targeted Drugs Transform Survival
According to Dr. Juan Cundom, medical oncologist and head of the Clinical Oncology Service at the Instituto Alfredo Lanari (UBA) and a clinical research representative at IADT, molecular biology insights have transformed daily medical practice.
“The appearance of new drugs allows mayores tasas de supervivencia, incluso en pacientes con diagnósticos avanzados, además de una mejora significativa en la calidad de vida y la tolerancia a los tratamientos,” Dr. Cundom stated, noting that immunotherapy and targeted therapies have revolutionized cancer care over the past 20 years.
These developments have made the chronification of previously lethal cancer types a clinical reality. Patients can often manage the disease as a long-term condition while maintaining a high quality of life.
Multidisciplinary Teams and Direct Patient Access
Participation in clinical trials provides patients with access to innovative therapies alongside standard diagnostic and treatment protocols. According to IADT study documentation, participants and their health coverages are exempt from research-associated costs, and facilities implement procedures to protect sensitive data.
Dr. Cundom emphasized the broader impact of trial participation, noting that it offers early access to new treatments while contributing to future patient care.
The execution of these clinical studies relies on multidisciplinary teams. At IADT, principal clinical studies coordinator Lic. Yésica Fontela works alongside research physicians, pharmacists, biochemists, diagnostic imaging specialists, and nursing professionals to manage patient evaluations and maintain protocol safety.
Regional Leadership and the Push Toward Precision Medicine
Oncological clinical research represents 30% of all pharmacological research across the country, securing a prominent position in Latin American oncological research. Multinational protocols generate therapeutic options for local patients while establishing Argentine researchers as key contributors to global therapy development.
Looking forward, Dr. Cundom noted that the focus is shifting toward precision medicine. The objective centers on patient selection to maximize therapeutic benefits and reduce adverse effects by leveraging molecular biology, advanced diagnostic platforms, artificial intelligence, and optimized regulatory timelines.
Related reading